How we help

We identify evidence gaps, assess feasibility and clarify the assumptions that matter before recommending an analytical approach.

• Systematic and targeted literature reviews
• Protocol development, including search strategy and PICOS scoping
• Feasibility assessments for indirect comparisons
• Identification of effect modifiers and prognostic factors
• AI-assisted systematic searching and screening

End-to-end execution of indirect treatment comparisons and related analyses, tailored to your data constraints and decision context. Methodological design is always founder-led.

• Network meta-analysis and meta-regression, including Bayesian and ML-NMR approaches
• Population-adjusted indirect comparisons (MAIC, STC)
• External control analyses and target trial emulation
• Crossover / treatment-switching adjustment
• Surrogate endpoint analyses (trial- and patient-level)
• Survival modelling and extrapolation

Analyses and documentation aligned with submission requirements across agencies, plus support through the review process.

• NICE, EU JCA, CDA-AMC and other global HTA submissions
• Technical reports and reviewer question responses
• Regulatory-aligned methods and documentation
• Strategic methods guidance for submission teams

Help teams anticipate evidence needs early, select appropriate methods and build internal capabilities through tailored training.

• Estimand and trial design input
• Evidence strategy and ITC planning, including for multiple JCA PICOs
• Bespoke training on comparative effectiveness methods for pharma teams and CROs
• Best-practice workshops

Application of AI-assisted tools using a human-in-the-loop approach that includes expert review, transparent methods and documented quality assurance.

• AI-assisted screening and data extraction
• AI-supported feasibility assessments
• Expert oversight and documented QA at every step